We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future †.
- Authors
Gokengin, Deniz; Bursa, Dominik; Skrzat-Klapaczynska, Agata; Alexiev, Ivailo; Arsikj, Elena; Balayan, Tatevik; Begovac, Josip; Cicic, Alma; Dragovic, Gordana; Harxhi, Arjan; Aimla, Kerstin; Lakatos, Botond; Matulionyte, Raimonda; Mulabdic, Velida; Oprea, Cristiana; Papadopoulos, Antonios; Rukhadze, Nino; Sedlacek, Dalibor; Sojak, Lubomir; Tomazic, Janez
- Abstract
With no expected vaccine for HIV in the near future, we aimed to define the current situation and challenges for pre- and post-exposure prophylaxis (PrEP and PEP) in Central and Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited to respond to a 27-item survey including questions on PrEP (response rate 91.6%). PrEP was licensed in 68.2%; 95 centers offered PrEP and the estimated number on PrEP was around 9000. It was available in daily (40.1%), on-demand (13.3%), or both forms (33.3%). The access rate was <1–80%. Three major barriers for access were lack of knowledge/awareness among people who are in need (59.1%), not being reimbursed (50.0%), and low perception of HIV risk (45.5%). Non-occupational PEP was available in 86.4% and was recommended in the guidelines in 54.5%. It was fully reimbursed in 36.4%, only for accidental exposures in 40.9%, and was not reimbursed in 22.72%. Occupational PEP was available in 95.5% and was reimbursed fully. Although PrEP scale-up in the region has gained momentum, a huge gap exists between those who are in need of and those who can access PrEP. Prompt action is required to address the urgent need for PrEP scale-up in the CEE region.
- Subjects
EASTERN Europe; AIDS vaccines; RISK perception; PRE-exposure prophylaxis; PREVENTIVE medicine
- Publication
Vaccines, 2023, Vol 11, Issue 1, p122
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines11010122